Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Tables)

6 Months Ended

Jun. 30, 2019

We used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:


	For the three months ended June 30,				For the six months ended June 30,
	2019		2018		2019		2018
Expected volatility	108	%	109	%	108	%	109	%
Expected term	5 years		5 years		5 years		5 years
Risk-free interest rate	2.21	%	2.65	%	2.24	%	2.44	%
Expected dividend yield	—	%	—	%	—	%	—	%

The following table summarizes the options granted for the periods indicated:

The following table summarizes stock-based option compensation for the three and six months ended June 30, 2019 and 2018:


	For the three months ended June 30,				For the six months ended June 30,
	2019		2018		2019		2018
Research and development	$	1,009,000	$	900,000	$	2,041,000	$	1,744,000
General and administrative		669,000		1,773,000		1,740,000		2,829,000
Stock-based compensation expense included in operating expense		1,678,000		2,673,000		3,781,000		4,573,000

Total stock-based compensation expense		1,678,000		2,673,000		3,781,000		4,573,000
Tax benefit		—		—		—		—
Stock-based compensation expense, net of tax	$	1,678,000	$	2,673,000	$	3,781,000	$	4,573,000

The following table summarizes restricted common stock compensation expense for the three and six months ended June 30, 2019 and 2018:


	For the three months ended June 30,				For the six months ended June 30,
	2019		2018		2019		2018
Research and development	$	—	$	—	$	—	$	—
General and administrative		78,000		172,000		250,000		344,000
Stock-based compensation expense included in operating expense		78,000		172,000		250,000		344,000

Total stock-based compensation expense		78,000		172,000		250,000		344,000
Tax benefit		—		—		—		—
Stock-based compensation expense, net of tax	$	78,000	$	172,000	$	250,000	$	344,000